Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The Alzheimer's risk gene APOE4 doesn't just raise your odds of getting the disease — it actively damages brain blood vessels and clogs the brain's protein cleanup system. But here's the hopeful part: Mount Sinai researchers found they could reverse some of that damage in lab experiments, pointing to new treatment targets for Alzheimer's, Parkinson's, and other neurodegenerative diseases.
The Alzheimer's risk gene APOE4 doesn't just raise your odds of getting the disease — it actively drives brain damage in ways that may be treatable. Two new studies from Mount Sinai, published in Cell and Cell Stem Cell, reveal that APOE4 transforms blood-vessel support cells into scar-producing cells, fueling vascular damage and amyloid buildup around brain vessels. Crucially, blocking a signaling pathway called TGF-β reversed this process in lab models, suggesting vascular degeneration isn't just an end-stage consequence of Alzheimer's — it's a potentially stoppable driver.
The second study found that APOE4 causes cholesterol to accumulate inside astrocytes (brain support cells), overwhelming their waste-disposal system. The result: toxic alpha-synuclein protein — a hallmark of Parkinson's and Lewy body dementia — builds up and spreads to neurons. Both studies relied on "miBrains," 3D human brain tissue models grown from stem cells, which allowed researchers to observe disease processes in human-like tissue and rapidly test interventions.
Key Takeaways
Why it matters: With over 7 million Americans living with Alzheimer's, identifying reversible disease mechanisms is a significant step forward. These findings open new therapeutic avenues not just for Alzheimer's, but for Parkinson's and other neurodegenerative diseases — and the miBrain platform could help accelerate the path from lab discovery to real-world treatment.
